Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and profits thanks to an important cancer drug. It's developing other products ...

In this article, we will take a look at the 14 Best Biotech Stocks to Buy Right Now. The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the ...

Bloom Energy, AbbVie, Thermo Fisher Scientific, Aptevo Therapeutics, Lumentum, Danaher, and NeuroBo Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves ...

Benzinga’s Edge Stock Rankings system scores stocks across key measures including momentum, growth, value and quality. The momentum score serves as a key indicator for traders looking to capitalize on ...

A good chunk of those positions is in the biotech and healthcare industries. It is one of the few areas I am finding some values within. Biotech names also tend to be higher beta, meaning the options ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and profits thanks to an important cancer drug. It's developing other products ...